USPTO serial 79395780
NAVIGNOSTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 15, 2025
- Examiner
- EDWARDS, ALICIA COLLINS
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NAVIGNOSTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nicholas D. Wells
Nicholas D. Wells Legends Law Group, PLLC330 Main St.Kaysville, UT 84037United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Reactants for medical diagnosis; diagnostic preparations for medical purposes; diagnostic reagents for medical or veterinary use in in vitro diagnosis; reactants for medical diagnosis, particularly for usage with spatial single-cell proteomics reagents for diagnostic tests for medical use; diagnostic test reagents for veterinary use; diagnostic preparations for medical use; diagnostic radiopharmaceutical preparations for medical purposes; diagnostic substances for medical use; pharmaceutical products, medical and veterinary preparations, namely, pharmaceutical preparations for use in the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations for the diagnosis and treatment of cancer; pharmaceutical preparations for the diagnosis of diseases; diagnostic pharmaceutical preparations; pharmaceutical preparations for individual medical diagnosis; medical test kits comprising pharmaceutical preparations for cancer therapy; medical test kits comprising pharmaceutical preparations for use in oncology for cancer screening; medical test kits comprising pharmaceutical preparations for cancer diagnosis; medical test kits comprising pharmaceutical preparations for individual medical diagnosis in the field of protein imaging; diagnostic test kits comprising pathology slides for testing tissue samples; test kits for use in oncology comprising sample tubes for testing tissue samples; diagnostic test kits comprising laboratory equipment for sample preparation, processing and storage for cancer diagnosis; diagnostic test kits for individual medical diagnosis comprising sample collection equipment for tumour analysis | ACTIVE | — |
| 010 | Apparatus for tumour diagnosis, namely, Imaging Mass Cytometry (IMC) apparatus; medical apparatus, namely, spectrometers for machine learning-based spectrum analysis of human blood plasma; Multiplex protein imaging scanners for medical diagnosis; apparatus for clinical diagnosis, namely, digital imaging device; spectrum analysers for use in medical diagnosis; trace material analysers for medical use in diagnosis; apparatus used in implementing diagnosis tests designed to detect abnormal genetic mutations in proteins, namely, spatial proteomics tools; medical test kits for cancer testing; diagnostic, examination, and monitoring equipment, namely, multiplex protein imaging equipment; medical test kits comprising tissue sampling equipment for the use in oncology for cancer screening; medical test kits for cancer diagnosis; medical test kits comprising tissue analysis tools for individual diagnosis in the field of cancer therapy | ACTIVE | — |
| 042 | Scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of proteomics; oncological research; medical research in the field of oncological diagnostics; computer programming for medical data analysis for cancer diagnostics; development of personalized diagnostics products in the nature of data sampling, imaging and analysis for cancer treatment; software-as-a-service (SaaS) featuring software for use in cancer diagnosis; platform-as-a-service (PaaS) featuring software for use in cancer diagnosis; software-as-a-service (SaaS) featuring software for cell analysis for use in oncology; platform-as-a-service (PaaS) featuring software for cell analysis for use in oncology; software-as-a-service (SaaS) featuring software for medical and scientific research in the field of cancer treatment and diagnosis; platform-as-a-service (PaaS) featuring software for medical and scientific research in the field of cancer treatment and diagnosis; software-as-a-service (SaaS) featuring software using machine learning in the field of medical diagnosis and research, particularly for cancer research, treatment and diagnosis; platform-as-a-service (PaaS) featuring software using machine learning in the field of medical diagnosis and research, particularly for cancer research, treatment and diagnosis; computer programming in the field of using machine learning regarding medical diagnosis and research, particularly for cancer research, treatment and diagnosis; software as a service (SaaS) featuring software for the analysis of medical data, particularly for cancer research, treatment and diagnosis; software-as-a-service (SaaS) featuring software for the analysis of medical data, particularly for cancer research, treatment and diagnosis; platform-as-a-service (PaaS) featuring software for the analysis of medical data, particularly for cancer research, treatment and diagnosis; software as-a-service (SaaS) featuring software for the digital representation of tumours and tumour features; platform-as-a-service (PaaS) featuring software for the digital representation of tumours and tumour features; software as-a-service (SaaS) featuring software for high-resolution digital image representation of the molecular composition of cellular anomalies; platform-as-a-service (PaaS) featuring software for high-resolution digital image representation of the molecular composition of cellular anomalies; software as-a-service (SaaS) featuring software for high-resolution digital image representation of digital tumours; platform-as-a-service (PaaS) featuring software for high-resolution digital image representation of digital tumours; cancer diagnosis research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Navignostics AG
- Other trademarks owned by Navignostics AG
- Other trademarks owned by Navignostics AG
- Other trademarks owned by Andrea Jacobs
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named NAVIGNOSTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 23, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 2, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 6, 2026 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Feb 5, 2026 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Oct 31, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Oct 15, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 15, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 15, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 15, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 15, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 27, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 27, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 21, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 28, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 24, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 24, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 24, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 12, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 23, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 23, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 20, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 19, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 6, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 9, 2024 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| May 22, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 22, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 16, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |